International legal practice, Osborne Clarke, has advised a group of investors consisting of Imperial Innovations, Invesco Perpetual and Woodford Investment Management on the £50m Venture Capital funding of Cell Medica Limited.

For further information see here for the RNS.

Partner, Rob Wood, led the Osborne Clarke team assisted by Senior Associate Caroline Drummond.

Rob Wood comments:
“This is a significant deal in the Life Science sector, and it's likely to be one of the top five private company funding rounds in 2014”.

Earlier this year, Osborne Clarke advised Imperial Innovations, Invesco Perpetual and others on the £581m IPO of the biopharmaceutical company, Circassia.